|
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy Clinical research trials and Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy. Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy clinical trial. Participants frequently obtain the most expert healthcare available for their Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "M" Clinical Trials Conditions > Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy  Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
For Condition: Communicable Diseases,Opportunistic Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Patients are exposed to infectious agents regularly, regardless of their immunologic status. Traditionally clinicians have decided to institute prophylaxis based on epidemiologic factors, skin test (i.e. PPD), or immunologic parameters. A quantitative and specific method that is non-invasive, such as quantitative PCR, would be desirable to more precisely define those who would benefit from prophylaxis. Similarly, when patients develop disease and are being treated, quantitative, non-invasive techniques are needed to assess response to therapy. This project is designed to develop and test quantitative tests using blood, urine, or sputum samples.
Details: Patients are exposed to infectious agents regularly, regardless of their immunologic status. Traditionally clinicians have decided to institute prophylaxis based on epidemiologic factors, skin test (i.e. PPD), or immunologic parameters. A quantitative and specific method that is non-invasive, such as quantitative PCR, would be desirable to more precisely define those who would benefit from prophylaxis. Similarly, when patients develop disease and are being treated, quantitative, non-invasive techniques are needed to assess response to therapy. This project is designed to develop and test quantitative tests using blood, urine, or sputum samples.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Patients older than 18 years of age. Ability to give informed consent. No medical contraindication to phlebotomy. Epidemiologically at risk for tuberculosis or for an opportunistic infection. Patients who can identify a responsible health care provider as someone willing to provide clinical information and to receive medically important information.
Total Enrollment: 300
Location and Contact Information:
National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 950176; 95-I-0176
Study Start Date: August 29, 1995
Record last reviewed: February 25, 2000
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001477
Other Opportunistic Infections Studies:
1. Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
Related Studies:
Other Opportunistic Infections Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Monitoring Patients for Developing Communicable and Opportunistic Infections and for Responding to Therapy
|
|
|
|
|
|
|
|
